mHSPC COE

Best Practices for Successfully Implementing Triplet Therapy in mHSPC - Christopher Pieczonka

Details
Christopher Pieczonka discusses the management of metastatic hormone-sensitive prostate cancer with a focus on triple therapy. Dr. Pieczonka emphasizes that androgen deprivation therapy (ADT) is no longer the standard of care as monotherapy for metastatic prostate cancer, citing the ARASENS study's results, which demonstrate the overall survival benefit of adding docetaxel and Nubeqa to ADT. He su...

Treating Metastatic Hormone-Sensitive Prostate Cancer: Beyond Counting Metastases - Karim Fizazi

Details
Alicia Morgans discusses the evolving strategies for treating metastatic hormone-sensitive prostate cancer (mHSPC) with Karim Fizazi. Professor Fizazi critiques the traditional method of classifying metastatic disease by the volume of metastases, advocating for a more nuanced approach. He highlights recent phase three trials that suggest a shift away from simply categorizing disease into low and h...

Coordinating Complex Care in High-Volume mHSPC Through Multidisciplinary Communication - Jonathan Henderson & Sunil Kakadia

Details
Alicia Morgans convenes a discussion on managing high-volume metastatic hormone-sensitive prostate cancer, bridging the practices of urology and medical oncology with Jonathan Henderson and Sunil Kakadia, a medical oncologist from Genesis Oncology. They emphasize the importance of collaborative care in treating complex cases, like a patient presenting with high PSA levels, highlighting the multidi...

Optimizing mHSPC Care and Collaboration for Triplet Therapy - Jason Hafron & Elisabeth Heath

Details
Zach Klaassen facilitates a conversation on the continuum of care in metastatic hormone-sensitive prostate cancer (mHSPC) with Jason Hafron and Elisabeth Heath. The discussion underscores the importance of collaboration between urology and medical oncology, particularly in administering triplet therapy. Dr. Hafron highlights the evolution of their partnership, emphasizing shared knowledge and pati...

ARASENS Subgroup Analysis on Triplet Therapy Improves Outcomes for Black Patients with mHSPC, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen delve into the significance of racial disparities in prostate cancer treatment through a subgroup analysis of the ARASENS trial, which notably focused on Black patients. This pivotal trial assessed the efficacy of adding darolutamide to ADT and docetaxel in metastatic hormone-sensitive prostate cancer, revealing that Black patients, despite historically higher morta...

Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans

Details
Alicia Morgans presents a meta-analysis, undertaken with colleagues, analyzing 14 phase three trials on treatment intensification in metastatic hormone-sensitive prostate cancer. The study scrutinizes outcomes between older and younger patients, revealing that older patients exhibit a slightly diminished benefit from intensified treatments compared to their younger counterparts. Despite this, the...

Adopting a Multidisciplinary Approach to Optimize Treatment Decisions for Patients with Metastatic Prostate Cancer - Michael Williams & Mark Fleming

Details
Michael Williams and Mark Fleming discuss their collaborative approach in managing patients with metastatic prostate cancer. Drs. Williams and Fleming emphasize the importance of multidisciplinary care, sharing a case of a patient with high-volume disease treated with an oral LHRH antagonist and enzalutamide. They highlight the need for open communication and decision-making between specialties to...

LIBERTAS Trial Tests Less Treatment, Better Quality of Life in Responding mHSPC Patients - Arun Azad

Details
Arun Azad discusses the LIBERTAS trial focusing on metastatic hormone-sensitive prostate cancer treatment with ADT plus apalutamide. The trial, aimed at improving patient outcomes and quality of life, explores the efficacy of deescalating therapy for patients achieving a PSA of less than 0.2 nanograms per milliliter after six months. The study includes a diverse patient population, irrespective of...

Systematic Review Sheds Light on Treatment Intensification in Metastatic Prostate Cancer - Peter Goebell

Details
Zach Klaassen and Peter Goebell discuss a systematic review focused on treatment intensification for metastatic hormone-sensitive prostate cancer. Dr. Goebell's study aims to assess if scientific evidence, as outlined in guidelines, translates into real-world practice changes. The review, incorporating data from 344,000 patients globally, examines the application of doublets and triplets in treatm...

Analyzing mHSPC Patient Responses to ADT with Enzalutamide vs. Apalutamide - Benjamin Lowentritt

Details
Benjamin Lowentritt discusses metastatic hormone-sensitive prostate cancer (mHSPC) patients' responses to ADT combined with enzalutamide or apalutamide. Dr. Lowentritt explains the study's methodology, emphasizing the importance of a deep and quick PSA response as a positive outcome marker. Initial findings suggest a faster and more prevalent PSA90 response in patients treated with apalutamide com...